

RESEARCH

Open Access

Genetic inactivation of the Fanconi anemia gene *FANCC* identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents

Andreas Palagyi¹, Kornelia Neveling², Ursula Plinninger¹, Andreas Ziesch¹, Bianca-Sabrina Targosz³, Gerald U Denk¹, Stephanie Ochs¹, Antonia Rizzani¹, Daniel Meier², Wolfgang E Thasler⁴, Helmut Hanenberg⁵, Enrico N De Toni¹, Florian Bassermann³, Claus Schäfer¹, Burkhard Göke¹, Detlev Schindler² and Eike Gallmeier*¹

Abstract

Background: Inactivation of the Fanconi anemia (FA) pathway through defects in one of 13 FA genes occurs at low frequency in various solid cancer entities among the general population. As FA pathway inactivation confers a distinct hypersensitivity towards DNA interstrand-crosslinking (ICL)-agents, FA defects represent rational targets for individualized therapeutic strategies. Except for pancreatic cancer, however, the prevalence of FA defects in gastrointestinal (GI) tumors has not yet been systematically explored.

Results: A panel of GI cancer cell lines was screened for FA pathway inactivation applying FANCD2 monoubiquitination and FANCD2/RAD51 nuclear focus formation and a newly identified FA pathway-deficient cell line was functionally characterized. The hepatocellular carcinoma (HCC) line HuH-7 was defective in FANCD2 monoubiquitination and FANCD2 nuclear focus formation but proficient in RAD51 focus formation. Gene complementation studies revealed that this proximal FA pathway inactivation was attributable to defective FANCC function in HuH-7 cells. Accordingly, a homozygous inactivating *FANCC* nonsense mutation (c.553C > T, p.R185X) was identified in HuH-7, resulting in partial transcriptional skipping of exon 6 and leading to the classic cellular FA hypersensitivity phenotype; HuH-7 cells exhibited a strongly reduced proliferation rate and a pronounced G2 cell cycle arrest at distinctly lower concentrations of ICL-agents than a panel of non-isogenic, FA pathway-proficient HCC cell lines. Upon retroviral transduction of HuH-7 cells with *FANCC* cDNA, FA pathway functions were restored and ICL-hypersensitivity abrogated. Analyses of 18 surgical HCC specimens yielded no further examples for genetic or epigenetic inactivation of *FANCC*, *FANCF*, or *FANCG* in HCC, suggesting a low prevalence of proximal FA pathway inactivation in this tumor type.

Conclusions: As the majority of HCC are chemoresistant, assessment of FA pathway function in HCC could identify small subpopulations of patients expected to predictably benefit from individualized treatment protocols using ICL-agents.

Background

Fanconi anemia (FA) is a rare recessive disorder, characterized by congenital skeletal abnormalities, progressive bone marrow failure and an increased cancer susceptibility [1]. The disease is caused by bi-allelic mutations in one

of 13 FA genes, all of which have now been identified [2]. The FA genes appear to act in a common pathway of DNA damage signalling and DNA remodelling, distal parts of which interact with regulators of cell cycle control and DNA repair, especially the repair of DNA interstrand-crosslinks.

There are three consecutive compartments of the FA pathway [3]. The proximal compartment consists of eight FA proteins (A, B, C, E, F, G, L, and M), which form a

* Correspondence: eike.gallmeier@med.uni-muenchen.de

¹ Department of Medicine II, Campus Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany
Full list of author information is available at the end of the article

nuclear FA core complex upon activation. This complex functions as an E3 ligase and mediates the monoubiquitination of FANCD2 [4], which represents the central FA pathway protein. FANCI also becomes monoubiquitinated during this process [5,6] and cooperates with FANCD2 in the ID (FANCI/FANCD2) complex [7,8]. The activated proteins of the ID complex subsequently colocalize with proteins of the distal FA pathway compartment (FANCD1/BRCA2, FANCN, and FANCF) and with other DNA-repair proteins such as RAD51 at sites of DNA-damage. Cells having a defect in one of the proximal FA core complex genes are deficient in FANCD2/FANCI monoubiquitination and FANCD2/FANCI nuclear focus formation. Similarly, cells having a defect in one of the distal FA pathway genes *FANCD1* or *FANCN* are deficient in RAD51 focus formation [8-12]. Cells with a defect in one of the ID complex proteins lack the respective protein and are defective in monoubiquitination of the other. Thus, inactivation of the FA pathway can comprehensively be identified at the cellular level by assays detecting FANCD2 monoubiquitination and FANCD2/RAD51 focus formation.

FA pathway inactivation occurs sporadically in a variety of tumor types of non-FA patients, suggesting a role of the FA genes in tumor suppression or maintenance of genomic stability among the general population. Distal FA pathway inactivation via mutations in *FANCD1* occurs in familial cases of breast (2-25%) [13] and ovarian cancer (2-6%) [14], in familial cases of pancreatic cancer (17%) [15] and in sporadic cancers of various tumor entities [16-18]. In comparison, genetic inactivation of the proximal FA pathway appears to occur infrequently in tumors among the general population and has, in terms of GI cancers, yet only been reported in pancreatic cancer, where it was associated with rare mutations in *FANCC* or *FANCG* [19,20]. In addition, germline mutations of *FANCC* might contribute to the tumorigenesis or tumor progression of pancreatic cancer [20-22]. Finally, epigenetic inactivation of the proximal FA pathway via hypermethylation of *FANCF* has been reported in a variety of tumor entities [23-27], but its significance is not yet well understood [28,29].

Unlike the setting in FA patients, FA pathway-deficient tumors arising in patients of the general population harbor the FA gene defect exclusively in the tumor cells, whereas stroma and all other non-malignant cells lack the defect, thus representing a tumor-specific, absolute biochemical difference [30]. As FA pathway-deficient cells are hypersensitive to ICL-agents and PARP inhibitors, FA pathway inactivation in tumors represents a promising target for rational, genotype-based anticancer therapy [31-38].

The prevalence of FA pathway defects has not yet been systematically investigated in GI cancer. We assessed

proximal and distal FA pathway function in 48 cell lines derived from gastric, pancreatic, colorectal, hepatocellular and cholangiocellular carcinomas applying assays for FANCD2 monoubiquitination and FANCD2/RAD51 focus formation [39]. We newly identified a single cell line, HuH-7, derived from a hepatocellular carcinoma (HCC), which exhibited a proximal FA pathway defect, ascribable to genetic *FANCC* inactivation. When compared to four other HCC cell lines, HuH-7 cells exhibited an increased sensitivity towards ICL-agents, which was reversible in these cells by genetic correction through *FANCC* overexpression. Our data represent the first evidence for genetic inactivation of the proximal FA pathway in HCC and further support the assumption that genetic inactivation of the proximal FA pathway is a rare event in solid tumors among the general population.

Results

GI cancer cell line-screening identifies proximal FA pathway-deficiency in HuH-7 cells

48 gastrointestinal cancer cell lines (18 colorectal, 15 pancreatic, 8 gastric, 5 hepatocellular and 2 cholangiocellular carcinomas) were screened for proximal and distal FA pathway inactivation using FANCD2 immunoblotting, FANCD2 and RAD51 nuclear focus formation (Fig. 1A, Table 1). Results on FA pathway inactivation in pancreatic cancer cell lines have been previously reported and were confirmed, including defective FANCD2 monoubiquitination due to inactivating mutations in *FANCG* and *FANCC* in Hs766T and PL11 [20,22], respectively, and defective RAD51 focus formation due to an inactivating *FANCD1* mutation in Capan-1 [17]. Among all samples newly tested in the present study, we identified one cell line without detectable FANCD2 monoubiquitination, the HCC line HuH-7 (Fig. 1A). To stimulate previously undetectable FANCD2 monoubiquitination, HuH-7 cultures were pre-treated with mitomycin C (MMC) at 100 nM for 24 h. Despite such challenge, HuH-7 did not display any trace of monoubiquitinated FANCD2. RKO cells and derived clones harboring an engineered disruption of *FANCG* or *FANCC* were used as controls [36] (Fig. 1B). Likewise, no FANCD2 focus formation was observed in HuH-7 after treatment with irradiation (IR) at 15 Gy 6 h prior to workup (Fig. 2A). In contrast, RAD51 focus formation was readily detectable (Fig. 2B), confirming a proximal FA pathway defect, whereas distal FA/BRCA pathway function remained undisturbed.

Gene complementation studies reveal defective FANCC function in HuH-7 cells

To identify the FA gene responsible for proximal FA pathway inactivation, HuH-7 cells were transduced with retroviral constructs containing full-length cDNAs of *FANCA*, *FANCB*, *FANCC*, *FANCE*, *FANCF*, *FANCG* or

Table 1: FANCD2- and RAD51-nuclear focus formation in 48 GI cancer cell lines

Cell line	Cancer type	FANCD2	RAD51	Cell line	Cancer type	FANCD2	RAD51
AGS	gastric	+	+	L3.6pl	pancreatic	+	+
AsPC-1	pancreatic	+	+	LoVo	colorectal	+	+
AZ-521	gastric	+	+	LS1034	colorectal	+	+
BxPC-3	pancreatic	+	+	LS513	colorectal	+	+
Caco-2	colorectal	+	+	MIA PaCa-2	pancreatic	+	+
Capan-1	pancreatic	+	-	MKN 45	gastric	+	+
Capan-2	pancreatic	+	+	MKN 7	gastric	+	+
CFPAC-1	pancreatic	+	+	NCI-N87	gastric	+	+
Chang	hepatocellular	+	+	PANC-1	pancreatic	+	+
CoGa 12	colorectal	+	+	PL11	pancreatic	-	+
CoGa 5	colorectal	+	+	PL3	pancreatic	+	+
CoGa 5L	colorectal	+	+	PL45	pancreatic	+	+
Colo 320	colorectal	+	+	PL5	pancreatic	+	+
DLD-1	colorectal	+	+	PL8	pancreatic	+	+
EGI-1	cholangiocellular	+	+	PLCPRF5	hepatocellular	+	+
HCA-7	colorectal	+	+	SNU-1	gastric	+	+
HCT 116	colorectal	+	+	SNU-5	gastric	+	+
Hep3B	hepatocellular	+	+	SU.86.86	pancreatic	+	+
HepG2	hepatocellular	+	+	SW48	colorectal	+	+
Hs766T	pancreatic	-	+	SW480	colorectal	+	+
HT-29	colorectal	+	+	SW620	colorectal	+	+
HuH-7	hepatocellular	-	+	SW948	colorectal	+	+
Isreco 1	colorectal	+	+	TFK-1	cholangiocellular	+	+
KATO III	gastric	+	+	WiDr	colorectal	+	+

(+) detectable or (-) no detectable nuclear focus formation of FANCD2 or RAD51, respectively, in the indicated cell lines, 6 h after treatment with IR at 15 Gy. FA pathway-deficient cell lines are depicted in bold.


FANCL. FANCD2 monoubiquitination was assessed following exposure of the transduced cultures to MMC. Restoration of FANCD2 monoubiquitination was observed only after complementation of HuH-7 cells with the *FANCC* gene construct, whereas all other constructs had no discernible effect (Fig. 3A). Consequently, exogenous FANCC protein expression was confirmed in *FANCC*-transduced HuH-7 cultures (Fig. 3B). To validate functional FA pathway restoration upon transduction of *FANCC*-cDNA, the cell cycle profiles of the transduced cells were analyzed 48 h after treatment with MMC. The pronounced G2 arrest, observed in non-*FANCC*-complemented HuH-7 cells was restored to normal specifically after transduction with *FANCC*, but not after transduction with any of the other FA or control constructs (Fig. 3C).

HuH-7 cells harbor a homozygous inactivating nonsense FANCC mutation in exon 6

Direct genomic sequencing of the coding exons and adjacent intron portions of *FANCC* in HuH-7 revealed a homo- or hemizygous inactivating nonsense mutation c.553C > T, p.R185X in coding exon 6 (Fig. 3D). No other sequence changes were identified.

Aberrant splicing leads to a truncated FANCC mRNA lacking exon 6 in HuH-7 cells

Using reverse-transcription PCR (RT-PCR) with primers flanking a region that includes exon 6, we identified an additional truncated *FANCC* gene transcript in HuH-7 cells, which was not detectable in four HCC control cell lines Chang, Hep3B, HepG2 and PLCPRF5 (Fig. 3E). Upon gel-separation of the two RT-PCR products amplified from HuH-7 cDNA, direct sequencing confirmed



that the correctly sized band represented the reference *FANCC* sequence except for the described c.553C > T nonsense mutation, while the smaller band represented the reference *FANCC* sequence lacking exon 6, leading to a direct exon 5/7 junction (Fig. 3F).

HuH-7 cells are hypersensitive towards ICL-agents as compared to other HCC lines

Five HCC cell lines (Chang, Hep3B, HepG2, HuH-7 and PLCPRF5) were treated either with common ICL-agents (MMC, cisplatin and melphalan) or with common non-ICL chemotherapeutics (5-fluorouracil (5-FU), etoposide and doxorubicin). The sensitivity towards ICL-agents was

clearly dissimilar between the FA pathway-proficient cell line panel and *FANCC*-deficient HuH-7 cells, with the latter displaying a distinct hypersensitivity (inhibitory concentration 50% (IC₅₀) ratios [40] ranging between 3.4 to 18.6 as compared to the other HCC lines) (Fig. 4A, upper panel). In contrast, treatment with non-ICL chemotherapeutics did not distinguish HuH-7 as being most sensitive (Fig. 4A, lower panel). The most consistent difference in ICL-agent sensitivity between the FA-pathway proficient HCC cell lines and *FANCC*-deficient HuH-7 cells was observed using melphalan. This agent has previously been described to have the strongest effect among 8 ICL-agents tested in an isogenic FA cancer cell model




Figure 2 FANCD2 and RAD51 nuclear focus formation to assess proximal and distal FA pathway function. (A) FANCD2 nuclear focus formation in RKO cells (positive control), derived RKO *FANCG* *-/-* cells (negative control), and a panel of five HCC cell lines including HuH-7, either treated with IR at 15 Gy for 6 h or left untreated. HuH-7 and RKO *FANCG* *-/-* cells lacked FANCD2 focus formation. **(B)** RAD51 nuclear focus formation in HuH-7 cells either treated with IR at 15 Gy for 6 h or left untreated.




Figure 3 Gene complementation studies identifying an inactivating *FANCC* nonsense mutation in HuH-7. (A) FANCD2 monoubiquitination in FA pathway-proficient control HeLa cells and HuH-7 cells transfected with the indicated FA or control cDNA constructs. All cultures were exposed to MMC at 150 nM for 15 h. RAD50 served as loading control. Only transduction with *FANCC* restored FANCD2 monoubiquitination in HuH-7 cells. (B) FANCC immunoblotting using the indicated cell lysates. The nuclear protein p84 served as loading control. Only HuH-7 cells transfected with *FANCC* and FA pathway-proficient Hep3B control cells displayed FANCC protein. (C) Cell cycle distributions of HuH-7 cells transfected with the indicated FA or control cDNA constructs. All cultures were exposed to MMC at 33 nM for 15 h. Only transduction with *FANCC* abrogated the pronounced G2 cell cycle arrest upon MMC in HuH-7 cells. (D) Chromatogram of the homo- or hemizygous *FANCC* mutation (arrow) identified in HuH-7 cells. (E) RT-PCR using three different primer pairs amplifying a region from *FANCC* non-coding exon 1 to coding exon 5, or from coding exons 3 to 13, or from coding exons 7 to 13, respectively, using cDNA from five HCC cell lines. Only HuH-7 cells exhibited aberrant mRNA splicing lacking exon 6. (F) Direct sequencing of the two distinct RT-PCR products confirmed that the product having the correct size represented the reference *FANCC* sequence except for the c.553C > T mutation, whereas the shorter product lacked exon 6, exhibiting a direct exon 5/7 junction.

[36]. Cell cycle distributions of the five HCC cell lines, analyzed upon treatment with MMC for 48 h, revealed a pronounced G2 arrest (defined here by a fraction of >40% of cells in G2) [36] at low MMC concentrations (25 nM) only in HuH-7 cells (Fig. 4B), whereas a similar G2 arrest was achieved in a dose-dependent manner in all HCC cell lines except PLCPRF5 at higher MMC concentrations (50 to 100 nM) (Fig. 4C).

ICL-hypersensitivity of HuH-7 cells is abrogated upon exogenous *FANCC* expression

HuH-7 cells were stably transduced using retroviral constructs containing either full length *FANCC*-cDNA (HuH-7/*FANCC*), tagged with recombinant influenza virus hemagglutinin (HA-tag), or empty vector (HuH-7/ev). Consecutively, exogenous *FANCC* expression was confirmed (Fig. 5A). HuH-7/*FANCC* cells, but not parental HuH-7 or HuH-7/ev control cells, displayed restored proximal FA-pathway function as demonstrated by constitutive and MMC-inducible [41] *FANCD2* monoubiquitination (Fig. 5B) as well as proficiency in *FANCD2* nuclear focus formation (Fig. 5C). Most importantly, sensitivity towards ICL-agents was significantly reduced in HuH-7/*FANCC* cells as compared to parental HuH-7 and HuH-7/ev control cells (Fig. 5D, upper panel), whereas sensitivity towards non-ICL-chemotherapeutics remained virtually unchanged (Fig. 5D, lower panel).

No evidence for inactivation of *FANCC*, *FANCG* or *FANCF* in 18 HCC tissue specimens

To assess the prevalence of proximal FA pathway inactivation in HCC, 18 surgical HCC tissue specimens were analyzed for inactivation of *FANCC*, *FANCF* or *FANCG* through screening for genetic mutations, epigenetic silencing through CpG hypermethylation or lack of mRNA-expression. On the genetic level, direct sequencing of the complete coding sequences of *FANCC*, *FANCF* and *FANCG* in 18 HCC samples identified a single not previously reported, heterozygous, synonymous *FANCC* sequence variant (c.813G > A) and two heterozygous, non-synonymous *FANCG* variants (c.20C > T, p.S7F; c.643C > A, p.Q215K) (Fig. 6A). No other sequence variants, especially no inactivating point mutations, small deletions, insertions, large intragenic deletions or complete homozygous gene deletions, were found. On the epigenetic level, HpaII-restriction assays yielded no evidence for *FANCC*-, *FANCF*- or *FANCG*-silencing through CpG hypermethylation (Fig. 6B) and consistently, *FANCC*-, *FANCF*- and *FANCG*-mRNA was detectable in all 18 HCC samples (Fig. 6C).

Discussion

We report here the identification and functional characterization of an inactivating nonsense *FANCC* mutation

in the HCC cell line HuH-7. This cell line was established from a well-differentiated HCC of a 57 year-old Japanese male patient [42], displays an aneuploid phenotype with an average number of 60 chromosomes, and is negative for HBV and HCV [43,44]. To our knowledge, this is the first evidence of genetic inactivation of the proximal FA pathway in a GI tumor entity other than pancreatic cancer.

The identified *FANCC* nonsense mutation c.553C > T, p.R185X in HuH-7 represents a known FA mutation, first described by Gibson et al. [45]. Interestingly, non-splice site nonsense mutations can cause exon-skipping through aberrant splicing [46], and accordingly, the c.553C > T mutation has been reported to cause partial transcriptional skipping of exon 6 of *FANCC* in an FA patient [45], a mechanism confirmed for HuH-7 in our study.

Unfortunately, no matched non-malignant tissue is available for HuH-7, precluding definitive genomic copy number analyses in regard to whether the identified *FANCC* mutation represents a homo- or hemizygous mutation in this cell line. However, according to copy number analyses by the Sanger Institute (Cambridge, UK) using high-density single nucleotide polymorphism (SNP) arrays (SNP 6.0) [47], HuH-7 harbors three nearly identical copies of the chromosomal arm 9q, where *FANCC* is located at 9q22.3, as evidenced by virtually exclusive homozygosity of all SNPs assessed on 9q. According to proposed evaluation models for the identification of LOH events where no matching normal tissue is available, these data are strongly suggestive (although not definitely evidentiary) of allelic loss of one copy of chromosome 9q including the non-mutated *FANCC* allele in the original tumor (or its precursor cells), followed by repeated duplication of the remaining chromosome 9q, including the mutated *FANCC* allele, later on [48-50]. Typical recurrent numerical chromosomal aberrations in HCC include losses on 1p, 4q, 8p, 13q, 16q, and 17p and gains on 1q, 8q, 16p and 20q [51]. Although chromosome 9 is rarely clonally altered on the cytogenetic level in HCC, LOH has been reported for several regions on chromosome 9 including the loci of the *FANCC* (9q22.3) and the *FANCG* (9p13) genes [52].

FA pathway defects in tumors require bi-allelic inactivation of one of at least 13 FA genes. On the one hand, these bi-allelic mutations could both be inherited, as applies to tumors occurring in FA-patients. On the other hand, mono-allelic germline mutations of distal FA pathway genes, such as *FANCD1*, *FANCN* or *FANCF*, confer low to medium penetrance susceptibility for breast/ovarian cancer [12,13,53] and, as applies to *FANCD1* and *FANCN*, also for pancreatic cancer [15,54-57]. In addition, inherited mono-allelic mutations of proximal FA pathway genes have been associated with the predisposi-




Figure 4 Hypersensitivity of HuH-7 cells specifically towards ICL-agents. (A) Cell proliferation assays to compare the sensitivity of five HCC cell lines towards ICL- and non-ICL-chemotherapeutic agents. HuH-7 cells were hypersensitive towards treatment with any of three ICL-agents as compared to four FA pathway-proficient HCC lines (upper panel: MMC, cisplatin, melphalan), with IC50 ratios ranging from 3.4- to 18.6-fold (arrows, indicated in red), but not towards any of three non-ICL-agents (lower panel: 5-FU, doxorubicin, etoposide). Error bars represent SEM of three independent experiments. **(B)** Flow cytometric cell cycle profiles of five HCC cell lines 48 h after treatment with MMC at the indicated concentrations. A pronounced G2 arrest (defined here as a cell fraction of >40% in G2 [36]) at low-dose MMC (25 nM) was observed only in HuH-7 cells. **(C)** Graphic representation of the cell cycle distributions from a representative experiment displaying the fraction of cells in G1, S or G2 at the indicated MMC concentrations for the indicated HCC cell lines. Arrows indicate the lowest dose at which a G2 arrest of more than 40% of the cells was observed.




Figure 5 Abrogation of the ICL-hypersensitivity phenotype in HuH-7 through exogenous FANCC expression. (A) Immunoblotting for the detection of FANCC-HA in parental HuH-7 cells (HuH-7) and HuH-7-derived clones retrovirally transduced with either empty vector-pMSCV (HuH-7/ev) or with pMSCV-FANCC (HuH-7/FANCC). HeLa cells transduced with pMSCV-FANCC were used as controls. CULLIN-1 served as loading control. FANCC-HA was detectable only in HuH-7/FANCC and control HeLa/FANCC cells. (B) FANCD2 monoubiquitination in parental HuH-7, HuH-7/ev and HuH-7/FANCC cells, respectively, either treated with MMC at 100 nM for 24 h or left untreated. RKO cells and derived RKO FANCC^{-/-} cells were used as controls. β -ACTIN served as loading control. Monoubiquitinated FANCD2 was detectable only in HuH-7/FANCC and parental RKO control cells and was inducible upon MMC-treatment, confirming correction of proximal FA pathway function through exogenous FANCC expression in HuH-7. (C) FANCD2 nuclear focus formation in parental HuH-7, HuH-7/ev and HuH-7/FANCC cells either treated with IR at 15 Gy for 6 h or left untreated. FANCD2 focus formation was detectable only in HuH-7/FANCC cells. (D) Cell proliferation assays to compare the sensitivity of parental HuH-7, HuH-7/ev and HuH-7/FANCC cells towards ICL- and non-ICL-chemotherapeutic agents. HuH-7/FANCC cells were less sensitive towards treatment with ICL-agents than parental and HuH-7/ev control cells (upper panel: MMC, cisplatin, melphalan), with IC₅₀ ratios ranging from 3.4- to 4.2-fold (arrows, indicated in red), whereas sensitivity towards non-ICL-agents (lower panel: 5-FU, doxorubicin, etoposide) remained virtually unchanged. Error bars represent SEM of three independent experiments.




Figure 6 Screening of 18 HCC tissues for inactivation of *FANCC*, *FANCF* or *FANCG*. **(A)** Chromatograms displaying the identified heterozygous sequence variants (arrows) in *FANCC* and *FANCG*. **(B)** PCR-based HpaII-restriction assays to determine methylation status of *FANCC*, *FANCF* and *FANCG* in 18 HCC tissues. The corresponding CpG island-containing regions were PCR-amplified before and after digestion using the indicated enzymes: U = undigested, H = HpaII digestion, M = MspI digestion. Universal methylated and unmethylated human DNA (hDNA) was used as controls. No hypermethylation of *FANCC*, *FANCF* or *FANCG* was detected in any of the 18 HCC samples. **(C)** RT-PCR to assess mRNA-expression of *FANCC*, *FANCF* and *FANCG* in 18 HCC tissues. All samples expressed *FANCC*-, *FANCF*- and *FANCG*-mRNA.

tion for or the accelerated development of certain tumors [21,54,55,58]. In particular, germline mutations of *FANCC* have been described in pancreatic cancer, associated with LOH in the tumor [21,22]. However, germline and somatic changes in *FANCC* and *FANCG* may have comparatively low penetrance for pancreatic cancer [55], which is supported by studies investigating germline mutations of upstream FA pathway genes in sporadic, yet FA-typical tumors among the general population [59]. Nevertheless, as the *FANCC* mutation in HuH-7 reported in our study represents an established FA mutation and was therefore most likely present in the germline of the patient in mono-allelic form, our data might indicate an increased risk for the development of HCC in individuals of the general population harboring this or other *FANCC* mutations.

The occurrence of an FA-associated *FANCC* mutation in HCC could also denote a tissue-specific susceptibility for the development of HCC in FA patients; The majority of solid malignancies seen in FA patients consists of head

and neck or gynaecologic carcinomas (5.3%), as reported in a large meta-analysis of 1300 cases [60], but also 2.8% of all FA patients developed liver tumors. These tumors manifested at a significantly younger age than other solid malignancies (median age: 13 years for liver tumors as compared to 26 years for other solid malignancies). In fact, the cumulative probability of liver tumors in FA patients has been estimated to be 46% by age 50 [60]. However, the significance of these data regarding a potential liver-specific cancer susceptibility of FA patients is complicated by the observation that many liver tumors do not proceed to malignancy during the life span of FA patients [60,61]. In addition, there appears to be a strong association between androgen therapy, which is frequently used for the treatment of bone marrow failure in FA, and the occurrence of liver tumors [60-63]. Nevertheless, HCC represented the majority (58%) of tumors of 36 FA patients with androgen-related liver tumors in one study [61]. Thus, the association of FA with HCC could be attributable both to the primary tumorigenic effects of

FA pathway inactivation in hepatocytes, as well as to potential secondary, amplifying or accelerating effects of androgen therapy in FA patients.

We demonstrated that HCC cells having an inactivated FA pathway display the classic cellular FA phenotype, including a specific hypersensitivity towards ICL-agents, illustrated in HuH-7 by a pronounced cell cycle arrest in G2 upon treatment with MMC at low concentrations and a strongly decreased proliferation rate as compared to a panel of non-isogenic HCC lines. Importantly, this ICL-hypersensitivity phenotype was reversed using an isogenic HuH-7 model of exogenous *FANCC* expression, confirming that ICL-hypersensitivity in these cells was attributable specifically to inactivation of *FANCC*. Of note however, IC50-ratios between *FANCC*-deficient and *FANCC*-proficient cells were partly smaller in the isogenic model than could have been expected from our results using the non-isogenic model. This observation could be attributable to FA pathway-independent ICL-sensitivity differences among the non-isogenic HCC cell lines, but could also provide further support for our previous hypothesis that constitutive exogenous *FANCC* over-expression does not completely substitute for physiologically regulated, endogenous *FANCC* expression [37,38].

It is well established that systemic chemotherapy lacks effectiveness in unselected HCC patients [64,65] and HCC are therefore considered largely chemoresistant, at least partially explaining the poor prognosis of this tumor entity [66]. Accordingly, guidelines are currently lacking also regarding the choice of chemotherapeutic agent to use in transarterial chemoembolization (TACE), one of the major treatment modalities for non-surgical patients at advanced HCC stages [67]. Our data indicate that non-FA patients having a FA-deficient HCC might predictably benefit from treatment using ICL-agents. Consequently, assessment of FA pathway function in HCC could facilitate individualized therapeutic approaches, using genotype-based patient stratification in regard to both systemic chemotherapy and TACE.

To get an estimate of the prevalence of *FANCC* inactivation in HCC, we sequenced cDNA derived from 18 surgical HCC tissue specimens to screen for genetic *FANCC* inactivation. We further screened these samples for hypermethylation of the *FANCC* promoter region and for lack of *FANCC* mRNA expression, as epigenetic *FANCC* inactivation has previously been reported in acute leukaemia and breast cancer [68,69]. Additionally, we included *FANCG* and *FANCF* in these analyses, as *FANCG* represents another proximal FA gene that has been described to be mutated in GI cancer, specifically in pancreatic cancer [20,22], while *FANCF* has been reported to be epigenetically inactivated in various tumor

types [23-25,27]. On the genetic level, we found no further inactivating alterations, especially no evidence for complete homozygous gene deletions, inactivating point mutations, small deletions or insertions, in *FANCC*, *FANCG* or *FANCF*, respectively. The detected *FANCG* variant c.20C > T, p.S7F has been reported in an FA patient of the complementation group G in addition to pathogenic *FANCG* mutations [70]. There is no information available on the nature of the c.643C > A, p.Q215K variant in *FANCG*. However, LOH or a second sequence variant was not detected in that tumor either. Additionally, since only two to three overlapping PCR reactions were used to amplify the complete coding sequences of *FANCC*, *FANCG* and *FANCF*, respectively, most potential large intragenic deletions would have been detected. However, this mechanism of proximal FA gene inactivation occurs almost exclusively in *FANCA*, whereas it appears to be extremely rare in *FANCC* and has not at all been described in *FANCG* [20,71-73]. On the epigenetic level, we found no evidence for hypermethylation of *FANCC*, *FANCG* or *FANCF* in any of the 18 samples. Consistently, *FANCC*, *FANCG* and *FANCF* were expressed in all samples on the mRNA level.

Our negative screening results for proximal FA pathway inactivation in HCC were not unexpected, as a hypothetical high prevalence should have become evident earlier during clinical trials - manifesting as a selective chemosensitivity of the majority of HCC towards ICL-agents. Nevertheless, the lack of FA mutations in 18 HCC does not rule out rare occurrences of proximal FA pathway inactivation in HCC and is consistent with previous reports on the low prevalence of proximal FA pathway inactivation in various tumor entities among the general population [20-22,26,29,68]. Future studies applying a higher sample number are required to definitely determine the prevalence of FA pathway inactivation in HCC.

Conclusions

In summary, we identified a HCC cell line harboring an inactivating mutation of the *FANCC* gene, specifically causing proximal FA pathway inactivation and the classic cellular ICL-hypersensitivity phenotype. Assessment of FA pathway function in HCC could thus represent a novel approach to identify small subgroups of HCC patients expected to predictably benefit from individualized treatment protocols using ICL-agents. However, as proximal FA pathway inactivation occurs at low frequency in HCC and other tumors among the general population, the development of rapid, economic and clinically applicable screening tests for proximal FA pathway inactivation, particularly in primary tumor tissues, remains an indispensable requirement to facilitate future clinical studies [38].

Materials and methods

Cell lines, culture conditions and HCC tissue samples

Cell lines PL3, PL5, PL8, PL11 and PL45 were kindly provided by S.E. Kern (Johns Hopkins University, Baltimore, Maryland). Cell lines AZ-521, CoGa-5, CoGa-5L, Coga-12, HCA-7, Isreco 1, MKN7, MKN45, NCI-N87 and L3.6pl were kindly donated by C.J. Bruns, M. Gerhard, F.T. Kolligs and M. Ogris (Technical University and Ludwig-Maximilians-University, Munich, Germany). The remaining cell lines were purchased from the European Collection of Cell Cultures (Sigma-Aldrich, Munich, Germany) or the American Type Culture Collection (LGC Standards, Wesel, Germany). RKO cells harboring an engineered disruption of the *FANCG* or *FANCC* gene have been described [36]. Cells were grown in DMEM supplemented with 10% fetal calf serum, L-glutamine and penicillin/streptomycin (PAA, Cölbe, Germany). The 18 HCC tissue samples were a kind gift of the Human Tissue and Cell Research-Trust (HTCR, Regensburg, Germany) and originated from HCCs that were surgically removed at the Ludwig-Maximilians-University (Munich, Germany).

Immunoblotting

Cells were treated with MMC (Sigma) at 100 nM for 24 h or left untreated. Consecutively, cells were lysed and protein extracts boiled and loaded on 6% polyacrylamide gels. After electrophoresis, proteins were transferred to PVDF membranes, which were blocked for 1 h in TBS-Triton X-100/2% milk before the primary antibody was applied overnight at 4°C (1:1000; anti-FANCD2 H-300, Santa Cruz Biotechnology, Heidelberg, Germany; anti-FANCC ab5065, Abcam, Cambridge, UK). HA-tagged FANCC was detected using an anti-HA antibody (1:1000; 12CA5, Santa Cruz). Antibodies directed against anti-RAD50 (1:5000; 13B3, GeneTex, San Antonio, TX), anti-p84 (1:1000; ab487, Abcam), anti-CUL1 (1:1000; 2H4C9, Invitrogen, Karlsruhe, Germany) or anti- β -ACTIN (1:10,000; AC-15, Sigma) served as loading controls. The membranes were washed and stained with anti-rabbit or anti-mouse HRP-conjugated antibodies (1:2000 to 1:10,000; GE Healthcare, Freiburg, Germany). Enhanced chemo-luminescence was elicited using SuperSignal West Pico substrate (Thermo Scientific, Schwerte, Germany) according to the manufacturer's instructions.

Nuclear focus formation assays

Experiments were performed as described before [74]. In brief, cells were grown on coverslips until ~80% confluency and were exposed to ionizing γ -radiation (IR) at 15 Gy using a cesium-137 irradiator. After incubation for 6 h, the cells were fixed using 3.7% formaldehyde and -20°C methanol. The cells were permeabilized using Triton X-100 and incubated in blocking buffer (PBS +2% bovine

serum albumin +0.5% Triton X-100) for 30 min. Consecutively, the cells were labelled using antibodies against FANCD2 (FI-17) or RAD51 (H-92) (Santa Cruz), respectively, for 2 h at room temperature. After washing, Alexa 488 goat anti-mouse or anti-rabbit antibody (Invitrogen) was applied for 1.5 h. Nuclei were counterstained using Hoechst 33342 (Roche Diagnostics, Mannheim, Germany), mounted and analyzed using a fluorescence microscope and Axiovision Software (Carl Zeiss AG; Oberkochen, Germany). The settings were kept identical for all samples.

Gene complementation studies

For FA complementation group determination, the cell line HuH-7 was transduced with retroviral constructs containing full-length cDNAs of *FANCA*, *FANCB*, *FANCC*, *FANCE*, *FANCF*, *FANCG* or *FANCL* and analyzed for cell cycle arrest upon treatment with MMC and for restoration of FANCD2 monoubiquitination, as previously described [26]. For isogenic studies, HuH-7 cells were stably transduced with either HA-tagged pMSCV-*FANCC* (HuH-7/*FANCC*) or the corresponding pMSCV empty control vector (HuH-7/ev).

gDNA sequencing

High molecular weight genomic DNA was prepared using a salting-out technique. Amplification of the *FANCC* exons was performed using published primer sets [75]. PCR products were purified using the GFX PCR DNA and Gel Band Purification kit (GE Healthcare). DNA sequencing of PCR products was performed using ABI-PRISM big-dye terminator chemistry on the ABI 310 instrument (Applied Biosystems, Darmstadt, Germany).

mRNA expression analyses and cDNA sequencing

Total RNA was extracted from surgical HCC tissues or cell lines using the NucleoSpin RNAII-Kit (Macherey-Nagel, Düren, Germany). RNA was reverse-transcribed using SuperScriptII reverse transcriptase (Invitrogen) and cDNA synthesized. Aberrant splicing of *FANCC* was determined by RT-PCR using the following primer pairs: Fwd 5'-ACTGCCCAAAGTCTGAAG-3' and Rev 5'-GTTTCAGACGCTAATGATAAAACCA-3' (spanning the first non-coding exon to coding exon 5), Fwd 5'-TTCTGGACAATCAAACTTAACTCC-3' and Rev 5'-GCTGCTGCTTCTGGACATT-3' (spanning the coding exons 3 to 13), Fwd 5'-GTAGTCTG CCTCTGGCTTCG-3' and Rev 5'-TTGAGGAGAAGGTGCCTGAT-3' (spanning the coding exons 7 to 13). Expression of *FANCC*, *FANCF* and *FANCG* mRNA was validated by RT-PCR as described previously [76]. For sequencing of the complete coding regions of *FANCC*, *FANCF* and *FANCG*, respectively, the corresponding cDNAs were amplified in two (*FANCF*) or three (*FANCC* and *FANCG*) overlapping PCR reactions (primer sets available on request). Amplified products

were sequenced using an ABI-Prism 3100-Avant Sequencer (Applied Biosystems) and sequence changes confirmed at the genomic level by gDNA sequencing. Reference genomic and cDNA sequences of the FA genes are available in the Fanconi Anemia Mutation Database [77].

Cell proliferation assays

The assays were performed over a broad range of concentrations covering 100% to 0% cell survival. 1,500-2,000 cells/well were plated in 96-well plates, allowed to adhere, and treated. Following incubation for 6 d, the cells were washed, lysed in 100 μ l H₂O, and 0.5% Picogreen (Molecular Probes, Invitrogen) was added. Fluorescence was measured (Cytofluor Series 4000, Applied Biosystems) and growth inhibition calculated as compared to the untreated control samples. Three independent experiments were performed per agent, with each data point reflecting triplicate wells. Error bars represent standard error of the mean (SEM) from three experiments.

Cell cycle analyses

Cells were seeded in 12-well plates and treated in duplicate for 48 h using various MMC concentrations (ranging from 25 to 200 nM) or were left untreated. The cells were fixed, stained with propidium iodide, and the DNA content per cell was measured using flow cytometry (FACS-Calibur, Becton Dickinson, Heidelberg, Germany). The data were analyzed using CELLQuest Pro software (Becton Dickinson). Alternatively, unfixed cells were stained with DAPI at a final concentration of 1 μ g/ml in a buffer containing 154 mM NaCl, 1 mM CaCl₂, 0.5 mM MgCl₂, 0.1 M TRIS, 0.2% BSA, and 0.1% NP40 for 30 min in the dark. Univariate flow histograms were recorded on an analytical, triple-laser equipped flow cytometer (LSRII, Becton Dickinson) using UV excitation of the DAPI dye. The resulting cell cycle distributions reflecting cellular DNA content were quantified using the MPLUS AV software package (Phoenix Flow Systems, San Diego, CA).

HpaII restriction enzyme methylation analysis

PCR-based HpaII-restriction assays were performed as described previously [23]. Transcriptional silencing through CpG hypermethylation was analyzed using published primer sets for *FANCF* [23] and *FANCC* [69], respectively. Primers used for *FANCG* were 5'-GAGTG-CAATGGCAGATG-3' (forward) and 5'-GCATGCTG-GGAGTCGTAGTA-3' (reverse). CpGenome universal methylated or unmethylated DNA (Chemicon - Millipore, Schwalbach am Taunus, Germany), respectively, were used as controls.

List of abbreviations

FA: Fanconi anemia; GI: gastrointestinal, HCC: hepatocellular carcinoma; ICL: interstrand-crosslink; IC50:

inhibitory concentration 50%; LOH: loss of heterozygosity; MMC: mitomycin C; SNP: single nucleotide polymorphism; RT-PCR: reverse-transcription PCR; TACE: transarterial chemoembolization

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AP was involved in study design, acquisition, analysis and interpretation of most of the data and drafted the manuscript. KN and DS carried out the complementation studies and parts of the genomic sequencing. UP, AZ, BT and DM performed and interpreted most of the immunoblotting assays. UP and AZ further performed and interpreted drug sensitivity assays and AZ additionally performed parts of the genomic sequencing. AR, EDT and AZ performed and interpreted the FACS analyses. SO performed immunoblotting, immunofluorescence and interpreted the nuclear focus formation assays. BT and FB engineered the stably transduced HuH-7 pMSCV lines. GUD provided and analyzed cholangiocellular carcinoma cell lines. WET provided the HCC tumor specimens. HH provided the retroviral constructs. EDT, CS, BG and DS participated in the conception and the design of the study or provided important intellectual content. EG conceived the project, coordinated the experiments, directed the analysis and interpretation of the data and wrote the final manuscript. All authors read and approved the final manuscript.

Acknowledgements

Tissue samples were obtained and experimental procedures were performed according to the guidelines of the charitable state controlled foundation HTCR, with the informed patient's consent [78]. We kindly acknowledge expert technical assistance with flow cytometry by Richard Friedl, Würzburg. This work was supported by grants to EG (DFG Ga762/3-1, Bavarian Academy of Sciences and Arts, Förderprogramm für Forschung und Lehre, Friedrich-Baur-Foundation, K.L. Weigand Fund) and to EDT (DFG To605/2-1).

Author Details

¹Department of Medicine II, Campus Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany, ²Department of Human Genetics, Biocenter, Julius-Maximilians-University, Am Hubland, 97074 Würzburg, Germany, ³Department of Medicine III, Klinikum rechts der Isar, Technical University Munich, Ismaningerstrasse 22, 81675 Munich, Germany, ⁴Department of Surgery, Campus Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany and ⁵Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Moorenstrasse 5, 40225 Düsseldorf, Germany

Received: 14 October 2009 Accepted: 28 May 2010

Published: 28 May 2010

References

1. D'Andrea AD, Grompe M: **The Fanconi anaemia/BRCA pathway.** *Nat Rev Cancer* 2003, **3**:23-34.
2. Wang W: **Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.** *Nat Rev Genet* 2007, **8**:735-748.
3. Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE: **Gene-Specific Selection Against Experimental Fanconi Anemia Gene Inactivation in Human Cancer.** *Cancer Biol Ther* 2007, **6**:654-660.
4. Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, Steltenpool J, Stone S, Dokal I, Mathew CG, et al.: **A human ortholog of archaean DNA repair protein Hef is defective in Fanconi anemia complementation group M.** *Nat Genet* 2005, **37**:958-963.
5. Levitus M, Joenje H, de Winter JP: **The Fanconi anemia pathway of genomic maintenance.** *Cell Oncol* 2006, **28**:3-29.
6. Dorsman JC, Levitus M, Rockx D, Roomans MA, Oostra AB, Haitjema A, Bakker ST, Steltenpool J, Schuler D, Mohan S, et al.: **Identification of the Fanconi anemia complementation group I gene, FANCI.** *Cell Oncol* 2007, **29**:211-218.
7. Sims AE, Spiteri E, Sims RJ III, Arita AG, Lach FP, Landers T, Wurm M, Freund M, Neveling K, Hanenberg H, et al.: **FANCI is a second monoubiquitinated member of the Fanconi anemia pathway.** *Nat Struct Mol Biol* 2007, **14**:564-567.

8. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER III, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ: **Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.** *Cell* 2007, **129**:289-301.
9. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL: **RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2.** *J Biol Chem* 1997, **272**:31941-31944.
10. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY: **BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.** *Cancer Res* 1999, **59**:3547-3551.
11. Godthelp BC, Wiegant WW, Waisfisz Q, Medhurst AL, Arwert F, Joenje H, Zdzienicka MZ: **Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2.** *Mutat Res* 2006, **594**:39-48.
12. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, et al.: **Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.** *Nat Genet* 2007, **39**:162-164.
13. Fackenthal JD, Olopade OI: **Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.** *Nat Rev Cancer* 2007, **7**:937-948.
14. Pal T, Permeth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, et al.: **BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.** *Cancer* 2005, **104**:2807-2816.
15. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE: **Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.** *Cancer Res* 2002, **62**:3789-3793.
16. King MC, Marks JH, Mandell JB: **Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.** *Science* 2003, **302**:643-646.
17. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE: **Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.** *Cancer Res* 1996, **56**:5360-5364.
18. Friedenson B: **BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.** *MedGenMed* 2005, **7**:60.
19. Heijden MS van der, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE: **In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.** *Clin Cancer Res* 2005, **11**:7508-7515.
20. Heijden MS van der, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE: **Functional defects in the fanconi anemia pathway in pancreatic cancer cells.** *Am J Pathol* 2004, **165**:651-657.
21. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, Petersen G: **Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.** *Cancer Res* 2005, **65**:383-386.
22. Heijden MS van der, Yeo CJ, Hruban RH, Kern SE: **Fanconi anemia gene mutations in young-onset pancreatic cancer.** *Cancer Res* 2003, **63**:2585-2588.
23. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD: **Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.** *Nat Med* 2003, **9**:568-574.
24. Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, Taniguchi T, D'Andrea A, Hodgson SV, Mathew CG, Joenje H: **Bi-allelic silencing of the Fanconi anemia gene FANCF in acute myeloid leukaemia.** *Br J Haematol* 2003, **123**:469-471.
25. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Vilella J, Meyer L, Schneider A, et al.: **Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.** *Cancer Res* 2004, **64**:2994-2997.
26. Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, Hoehn H, Hader C, Hartmann FH, Nanda I, Steinlein C, et al.: **Disruption of the FA/BRCA pathway in bladder cancer.** *Cytogenet Genome Res* 2007, **118**:166-176.
27. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: **Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.** *Oncogene* 2004, **23**:1000-1004.
28. Gallmeier E, Kern SE: **Genetic Pathways of Pancreatic Tumorigenesis.** In *"Disease of the Pancreas: Current Surgical Therapy": Genetic Pathways of Pancreatic Tumorigenesis* Edited by: Beger H, Cameron JL, Matsuno S. Heidelberg: Springer Verlag; 2007.
29. Ameziane N, Chen F, Leemans CR, Brakenhoff RH, Joenje H: **No evidence for FANCF gene silencing in head-and-neck squamous cell carcinomas.** *Cell Oncol* 2009, **31**:53-56.
30. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE: **Homozygous deletion map at 18q21.1 in pancreatic cancer.** *Cancer Res* 1996, **56**:490-494.
31. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T: **Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.** *Nature* 2005, **434**:913-917.
32. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al.: **Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.** *Nature* 2005, **434**:917-921.
33. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A: **BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.** *Cancer Biol Ther* 2005, **4**:934-936.
34. Gallmeier E, Kern SE: **Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition.** *Cancer Biol Ther* 2005, **4**:703-706.
35. Ashwell S, Zabludoff S: **DNA damage detection and repair pathways—recent advances with inhibitors of checkpoint kinases in cancer therapy.** *Clin Cancer Res* 2008, **14**:4032-4037.
36. Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C, Kern SE: **Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.** *Gastroenterology* 2006, **130**:2145-2154.
37. Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparikova J, Brabec V, Bachman KE, Kern SE: **High-throughput screening identifies novel agents eliciting hypersensitivity in fanconi pathway-deficient cancer cells.** *Cancer Res* 2007, **67**:2169-2177.
38. Gallmeier E, Kern SE: **Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models.** *Clin Cancer Res* 2007, **13**:4-10.
39. Heijden MS Van Der, Brody JR, Kern SE: **Functional screen of the fanconi anemia pathway in cancer cells by fancd2 immunoblot.** *Cancer Biol Ther* 2004, **3**:534-537. Epub 2004 Jun 2018
40. Hucl T, Gallmeier E, Kern SE: **Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.** *Cell Cycle* 2007, **6**:1336-1341.
41. Andreassen PR, D'Andrea AD, Taniguchi T: **ATR couples FANCD2 monoubiquitination to the DNA-damage response.** *Genes Dev* 2004, **18**:1958-1963.
42. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: **Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.** *Cancer Res* 1982, **42**:3858-3863.
43. Japanese Collection of Research Bioresources [<http://cellbank.nibio.go.jp/>]
44. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: **Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.** *Science* 1999, **285**:110-113.
45. Gibson RA, Hajianpour A, Murer-Orlando M, Buchwald M, Mathew CG: **A nonsense mutation and exon skipping in the Fanconi anaemia group C gene.** *Hum Mol Genet* 1993, **2**:797-799.
46. Valentine CR: **The association of nonsense codons with exon skipping.** *Mutat Res* 1998, **411**:87-117.
47. The Sanger Institute Cancer Cell Line Project [<http://www.sanger.ac.uk/genetics/CGP/CellLines/>]
48. Calhoun ES, Gallmeier E, Cunningham SC, Eshleman JR, Hruban RH, Kern SE: **Copy-number methods dramatically underestimate loss of heterozygosity in cancer.** *Genes Chromosomes Cancer* 2006, **45**(11):1070-1.
49. Calhoun ES, Hucl T, Gallmeier E, West KM, Arking DE, Maitra A, Iacobuzio-Donahue CA, Chakravarti A, Hruban RH, Kern SE: **Identifying Allelic Loss and Homozygous Deletions in Pancreatic Cancer without Matched Normals Using High-Density Single-Nucleotide Polymorphism Arrays.** *Cancer Res* 2006, **66**:7920-7928.
50. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D, Swamy S, Santarius T, Chen L, Widaa S, et al.: **PICNIC: an algorithm to predict**

- absolute allelic copy number variation with microarray cancer data. *Biostatistics* 11:164-175.
51. Wong CM, Ng IO: **Molecular pathogenesis of hepatocellular carcinoma.** *Liver Int* 2008, **28**:160-174.
52. Liew CT, Li HM, Lo KW, Leow CK, Lau WY, Hin LY, Lim BK, Lai PB, Chan JY, Wang XQ, et al.: **Frequent allelic loss on chromosome 9 in hepatocellular carcinoma.** *Int J Cancer* 1999, **81**:319-324.
53. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, et al.: **Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.** *Nat Genet* 2006, **38**:1239-1241.
54. Rogers CD, Couch FJ, Brune K, Martin ST, Philips J, Murphy KM, Petersen G, Yeo CJ, Hruban RH, Goggins M: **Genetics of the FANCA gene in familial pancreatic cancer.** *J Med Genet* 2004, **41**:e126.
55. Rogers CD, Heijden MS van der, Brune K, Yeo CJ, Hruban RH, Kern SE, Goggins M: **The genetics of FANCC and FANCG in familial pancreatic cancer.** *Cancer Biol Ther* 2004, **3**:167-169.
56. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, et al.: **Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.** *Science* 2009, **324**:217.
57. Gallmeier E, Hucl T, Winter JM, Kern SE: **No mutations identified in the Fanconi Anemia gene BRIP1 (BACH1, FANCI).** *NOGO* 2005, **10**:1.
58. Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, et al.: **Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer.** *Cancer Res* 2007, **67**:9591-9596.
59. Neveling K, Kalb R, Schindler D: **Cancer in Fanconi anemia and Fanconi anemia genes in cancer.** In *Fanconi Anemia - A Paradigmatic disease for the Understanding of Cancer and Aging* Edited by: Schindler D, Hoehn H. Basel: Karger; 2007:59-78.
60. Alter BP: **Cancer in Fanconi anemia, 1927-2001.** *Cancer* 2003, **97**:425-440.
61. Velazquez I, Alter BP: **Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions.** *Am J Hematol* 2004, **77**:257-267.
62. Johnson FL, Lerner KG, Siegel M, Feagler JR, Majerus PW, Hartmann JR, Thomas ED: **Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma.** *Lancet* 1972, **2**:1273-1276.
63. Sweeney EC, Evans DJ: **Hepatic lesions in patients treated with synthetic anabolic steroids.** *J Clin Pathol* 1976, **29**:626-633.
64. Llovet JM, Bruix J: **Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.** *Hepatology* 2003, **37**:429-442.
65. Lopez PM, Villanueva A, Llovet JM: **Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.** *Aliment Pharmacol Ther* 2006, **23**:1535-1547.
66. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: **Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.** *J Hepatol* 2001, **35**:421-430.
67. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: **Diagnosis and treatment of hepatocellular carcinoma.** *Gastroenterology* 2008, **134**:1752-1763.
68. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJ, Cloos J, Joenje H, Reinhardt D, Ossenkoppele GJ, et al.: **Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.** *Cell Oncol* 2008, **30**:299-306.
69. Sinha SM, Singh RD, Alam ND, Roy AD, Roychoudhury SD, Panda CD: **Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma.** *Mol Cancer* 2008, **7**:84.
70. Demuth I, Wlodarski M, Tipping AJ, Morgan NV, de Winter JP, Thiel M, Grasl S, Schindler D, D'Andrea AD, Altay C, et al.: **Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9.** *Eur J Hum Genet* 2000, **8**:861-868.
71. Morgan NV, Tipping AJ, Joenje H, Mathew CG: **High frequency of large intragenic deletions in the Fanconi anemia group A gene.** *Am J Hum Genet* 1999, **65**:1330-1341.
72. Rischewski JR, Gross M, Hanenberg H, Michael K, Schneppenheim R, Schindler D: **Mutation Spectrum of FANCC in Europe and DHLPC-Based Identification of a Large Deletion.** In *Fifteenth Annual Fanconi Anemia Research Fund Scientific Symposium* Houston, TX; 2003.
73. Neveling K, Endt D, Hoehn H, Schindler D: **Genotype-phenotype correlations in Fanconi anemia.** *Mutat Res* 2009, **668**:73-91.
74. Gallmeier E, Winter JM, Cunningham SC, Kahn SR, Kern SE: **Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX.** *Carcinogenesis* 2005, **26**:1811-1820.
75. Gibson RA, Buchwald M, Roberts RG, Mathew CG: **Characterisation of the exon structure of the Fanconi anaemia group C gene by vectorette PCR.** *Hum Mol Genet* 1993, **2**:35-38.
76. Snyder ER, Ricker JL, Chen Z, Waes CV: **Variation in cisplatin sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.** *Cancer Lett* 2007, **245**:75-80.
77. **The Fanconi Anemia Mutation Database** [<http://www.rockefeller.edu/fanconi/mutate/>]
78. Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irrgang B, Jauch KW: **Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany.** *Cell Tissue Bank* 2003, **4**:49-56.

doi: 10.1186/1476-4598-9-127

Cite this article as: Palagyi et al., Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents *Molecular Cancer* 2010, **9**:127

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

